» Articles » PMID: 36041813

Major Infections in Newly Diagnosed Systemic Lupus Erythematosus: an Inception Cohort Study

Overview
Journal Lupus Sci Med
Date 2022 Aug 30
PMID 36041813
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the risk of major infections and the relationship between major infections and mortality in patients with newly diagnosed SLE.

Methods: A newly diagnosed (<3 months) hospitalised Systemic Lupus Inception Cohort (hSLIC) in our centre during 1 January 2013 and 1 November 2020 was established. All patients were followed up for at least 1 year or until death. Patient baseline characteristics were collected. Major infection events were recorded during follow-up, which were defined as microbiological/clinical-based diagnosis treated with intravenous antimicrobials. The cohort was further divided into a training set and a testing set. Independent predictors of major infections were identified using multivariable logistic regression analysis. Kaplan-Meier survival analyses were conducted.

Results: Among the 494 patients enrolled in the hSLIC cohort, there were 69 documented episodes of major infections during the first year of follow-up in 67 (14%) patients. The major infection events predominantly occurred within the first 4 months since enrolment (94%, 65/69) and were associated with all-cause mortality. After adjustments for glucocorticoid and immunosuppressant exposure, a prediction model based on SLE Disease Activity Index >10, peripheral lymphocyte count <0.8×10/L and serum creatinine >104 µmol/L was established to identify patients at low risk (3%-5%) or high risk (37%-39%) of major infections within the first 4 months.

Conclusions: Newly onset active SLE is susceptible to major infections, which is probably due to underlying profound immune disturbance. Identifying high-risk patients using an appropriate prediction tool might lead to better tailored management and better outcome.

Citing Articles

Fever of Unknown Origin in a Young Woman With Multiple Comorbidities: A Diagnostic Challenge.

Kumar S, Rincon-Vazquez C, Ward P, Collignon T, Tumarinson T Cureus. 2025; 17(2):e78361.

PMID: 40041647 PMC: 11875836. DOI: 10.7759/cureus.78361.


SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort.

Rua-Figueroa I, Garcia de Yebenes M, Martinez-Barrio J, Izquierdo M, Calvo Alen J, Fernandez-Nebro A Lupus Sci Med. 2024; 11(1).

PMID: 38589223 PMC: 11015315. DOI: 10.1136/lupus-2023-001096.


Major Infections of Newly Diagnosed Childhood-Onset Systemic Lupus Erythematosus.

Bao S, Lu J, Huang H, Jin Y, Ding F, Yang Z J Multidiscip Healthc. 2023; 16:1455-1462.

PMID: 37251105 PMC: 10225143. DOI: 10.2147/JMDH.S408596.


Systemic lupus erythematosus: latest insight into etiopathogenesis.

Akhil A, Bansal R, Anupam K, Tandon A, Bhatnagar A Rheumatol Int. 2023; 43(8):1381-1393.

PMID: 37226016 PMC: 10208557. DOI: 10.1007/s00296-023-05346-x.


Tuberculosis remains a leading contributor to morbidity due to serious infections in Indian patients of SLE.

Chatterjee R, Pattanaik S, Misra D, Agarwal V, Lawrence A, Misra R Clin Rheumatol. 2023; 42(8):2079-2090.

PMID: 37040053 PMC: 10088612. DOI: 10.1007/s10067-023-06592-x.


References
1.
Yu C, Chang K, Chiu C, Chiang B, Han S, Wang S . Defective phagocytosis, decreased tumour necrosis factor-alpha production, and lymphocyte hyporesponsiveness predispose patients with systemic lupus erythematosus to infections. Scand J Rheumatol. 1989; 18(2):97-105. DOI: 10.3109/03009748909099924. View

2.
Kang I, Park S . Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003; 15(5):528-34. DOI: 10.1097/00002281-200309000-00002. View

3.
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis J . 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089. View

4.
Zhao K, Xie H, Li L, Esdaile J, Avina-Zubieta J . Increased risk of severe infections and mortality in patients with newly diagnosed systemic lupus erythematosus: a population-based study. Rheumatology (Oxford). 2021; 60(11):5300-5309. DOI: 10.1093/rheumatology/keab219. View

5.
Lu Z, Li J, Ji J, Gu Z, Da Z . Mortality prediction in systemic lupus erythematosus patients with pulmonary infection. Int J Rheum Dis. 2019; 22(6):1077-1083. DOI: 10.1111/1756-185X.13555. View